Differentiation shifts from a reversible to an irreversible heterochromatin state at the DM1 locus.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
05
09
2021
accepted:
25
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
epublish
Résumé
Epigenetic defects caused by hereditary or de novo mutations are implicated in various human diseases. It remains uncertain whether correcting the underlying mutation can reverse these defects in patient cells. Here we show by the analysis of myotonic dystrophy type 1 (DM1)-related locus that in mutant human embryonic stem cells (hESCs), DNA methylation and H3K9me3 enrichments are completely abolished by repeat excision (CTG2000 expansion), whereas in patient myoblasts (CTG2600 expansion), repeat deletion fails to do so. This distinction between undifferentiated and differentiated cells arises during cell differentiation, and can be reversed by reprogramming of gene-edited myoblasts. We demonstrate that abnormal methylation in DM1 is distinctively maintained in the undifferentiated state by the activity of the de novo DNMTs (DNMT3b in tandem with DNMT3a). Overall, the findings highlight a crucial difference in heterochromatin maintenance between undifferentiated (sequence-dependent) and differentiated (sequence-independent) cells, thus underscoring the role of differentiation as a locking mechanism for repressive epigenetic modifications at the DM1 locus.
Identifiants
pubmed: 38627364
doi: 10.1038/s41467-024-47217-4
pii: 10.1038/s41467-024-47217-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3270Informations de copyright
© 2024. The Author(s).
Références
Li, E. & Zhang, Y. DNA methylation in mammals. Cold Spring Harb. Perspect. Biol. 6, a019133 (2014).
pubmed: 24789823
pmcid: 3996472
doi: 10.1101/cshperspect.a019133
Cedar, H. & Bergman, Y. Programming of DNA methylation patterns. Annu Rev. Biochem. 81, 97–117 (2012).
pubmed: 22404632
doi: 10.1146/annurev-biochem-052610-091920
Moore, L. D., Le, T. & Fan, G. DNA methylation and its basic function. Neuropsychopharmacology 38, 23–38 (2013).
pubmed: 22781841
doi: 10.1038/npp.2012.112
Zoghbi, H. Y. & Beaudet, A. L. Epigenetics and human disease. Cold Spring Harb. Perspect. Biol. 8, a019497 (2016).
pubmed: 26834142
pmcid: 4743078
doi: 10.1101/cshperspect.a019497
Park, C. Y. et al. Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. Cell Rep. 13, 234–241 (2015).
pubmed: 26440889
doi: 10.1016/j.celrep.2015.08.084
Xie, N. et al. Reactivation of FMR1 by CRISPR/Cas9-mediated deletion of the expanded CGG-repeat of the fragile X chromosome. PLoS One 11, e0165499 (2016).
pubmed: 27768763
pmcid: 5074572
doi: 10.1371/journal.pone.0165499
Aslanidis, C. et al. Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature 355, 548–551 (1992).
pubmed: 1346925
doi: 10.1038/355548a0
Brook, J. D. et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 69, 385 (1992).
pubmed: 1568252
Mankodi, A. et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289, 1769–1773 (2000).
pubmed: 10976074
doi: 10.1126/science.289.5485.1769
Steinbach, P., Gläser, D., Vogel, W., Wolf, M. & Schwemmle, S. The DMPK gene of severely affected myotonic dystrophy patients is hypermethylated proximal to the largely expanded CTG repeat. Am. J. Hum. Genet. 62, 278–285 (1998).
pubmed: 9463318
pmcid: 1376887
doi: 10.1086/301711
Spits, C., Seneca, S., Hilven, P., Liebaers, I. & Sermon, K. Methylation of the CpG sites in the myotonic dystrophy locus does not correlate with CTG expansion size or with the congenital form of the disease. J. Med. Genet. 47, 700–703 (2010).
pubmed: 20644219
doi: 10.1136/jmg.2009.074211
López-Castel, A. et al. Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum. Mol. Genet. 20, 1–15 (2011).
pubmed: 21044947
doi: 10.1093/hmg/ddq427
Brouwer, J. R., Huguet, A., Nicole, A., Munnich, A. & Gourdon, G. Transcriptionally repressive chromatin remodelling and CpG methylation in the presence of expanded CTG-repeats at the DM1 locus. J. Nucleic Acids 2013, 567435–451 (2013).
pubmed: 24455202
pmcid: 3884603
doi: 10.1155/2013/567435
Yanovsky-Dagan, S. et al. Uncovering the role of hypermethylation by CTG expansion in myotonic dystrophy type 1 using mutant human embryonic stem cells. Stem Cell Rep. 5, 221–231 (2015).
doi: 10.1016/j.stemcr.2015.06.003
Barbé, L. et al. CpG methylation, a parent-of-origin effect for maternal-biased transmission of congenital myotonic dystrophy. Am. J. Hum. Genet. 100, 488–505 (2017).
pubmed: 28257691
pmcid: 5339342
doi: 10.1016/j.ajhg.2017.01.033
Légaré, C. et al. gene DNA methylation levels are associated with muscular and respiratory profiles in DM1. Neurol. Genet. 5, e338 (2019).
pubmed: 31334355
pmcid: 6568328
doi: 10.1212/NXG.0000000000000338
Wakimoto, H. et al. Characterization of cardiac conduction system abnormalities in mice with targeted disruption of Six5 gene. J. Inter. Card. Electrophysiol. 7, 127–135 (2002).
doi: 10.1023/A:1020881520353
Sarkar, P. S. et al. Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts. Nat. Genet. 25, 110–114 (2000).
pubmed: 10802668
doi: 10.1038/75500
Sarkar, P. S., Paul, S., Han, J. & Reddy, S. Six5 is required for spermatogenic cell survival and spermiogenesis. Hum. Mol. Genet. 13, 1421–1431 (2004).
pubmed: 15163633
doi: 10.1093/hmg/ddh161
Thornton, C. A., Wymer, J. P., Simmons, Z., McClain, C. & Moxley, R. T. Expansion of the myotonic dystrophy CTG repeat reduces expression of the flanking DMAHP gene. Nat. Genet. 16, 407–409 (1997).
pubmed: 9241283
doi: 10.1038/ng0897-407
Klesert, T. R., Otten, A. D., Bird, T. D. & Tapscott, S. J. Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP. Nat. Genet. 16, 402–406 (1997).
pubmed: 9241282
doi: 10.1038/ng0897-402
Klesert, T. R. et al. Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy. Nat. Genet. 25, 105–109 (2000).
pubmed: 10802667
doi: 10.1038/75490
Korade-Mirnics, Z. et al. Myotonic dystrophy: tissue-specific effect of somatic CTG expansions on allele-specific DMAHP/SIX5 expression. Hum. Mol. Genet. 8, 1017–1023 (1999).
pubmed: 10332033
doi: 10.1093/hmg/8.6.1017
Cho, D. H. et al. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol. Cell 20, 483–489 (2005).
pubmed: 16285929
doi: 10.1016/j.molcel.2005.09.002
van Agtmaal, E. L. et al. CRISPR/Cas9-Induced (CTG⋅CAG). Mol. Ther. 25, 24–43 (2017).
pubmed: 28129118
pmcid: 5363205
Salvatori, S. et al. Decreased expression of DMPK: correlation with CTG repeat expansion and fibre type composition in myotonic dystrophy type 1. Neurol. Sci. 26, 235–242 (2005).
pubmed: 16193250
doi: 10.1007/s10072-005-0466-x
Furling, D., Lemieux, D., Taneja, K. & Puymirat, J. Decreased levels of myotonic dystrophy protein kinase (DMPK) and delayed differentiation in human myotonic dystrophy myoblasts. Neuromuscul. Disord. 11, 728–735 (2001).
pubmed: 11595515
doi: 10.1016/S0960-8966(01)00226-7
Singh Nanda, J., Kumar, R. & Raghava, G. P. dbEM: A database of epigenetic modifiers curated from cancerous and normal genomes. Sci. Rep. 6, 19340 (2016).
pubmed: 26777304
pmcid: 4726101
doi: 10.1038/srep19340
Liao, J. et al. Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. Nat. Genet. 47, 469–478 (2015).
pubmed: 25822089
pmcid: 4414868
doi: 10.1038/ng.3258
Khrabrova, D. A. et al. Functional analysis of DNMT3A DNA methyltransferase mutations reported in patients with acute myeloid leukemia. Biomolecules 10, 8 (2019).
pubmed: 31861499
doi: 10.3390/biom10010008
Skvortsova, E. V., Sinenko, S. A. & Tomilin, A. N. Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state. Oncotarget 9, 35241–35250 (2018).
pubmed: 30443291
pmcid: 6219659
doi: 10.18632/oncotarget.26235
Lister, R. et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471, 68–73 (2011).
pubmed: 21289626
pmcid: 3100360
doi: 10.1038/nature09798
Huntriss, J. et al. Expression of mRNAs for DNA methyltransferases and methyl-CpG-binding proteins in the human female germ line, preimplantation embryos, and embryonic stem cells. Mol. Reprod. Dev. 67, 323–336 (2004).
pubmed: 14735494
doi: 10.1002/mrd.20030
Kato, Y. et al. Role of the Dnmt3 family in de novo methylation of imprinted and repetitive sequences during male germ cell development in the mouse. Hum. Mol. Genet 16, 2272–2280 (2007).
pubmed: 17616512
doi: 10.1093/hmg/ddm179
Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247–257 (1999).
pubmed: 10555141
doi: 10.1016/S0092-8674(00)81656-6
Chen, T., Tsujimoto, N. & Li, E. The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at pericentric heterochromatin. Mol. Cell Biol. 24, 9048–9058 (2004).
pubmed: 15456878
pmcid: 517890
doi: 10.1128/MCB.24.20.9048-9058.2004
van den Boogaard, M. L. et al. Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy. Am. J. Hum. Genet 98, 1020–1029 (2016).
pubmed: 27153398
pmcid: 4863565
doi: 10.1016/j.ajhg.2016.03.013
Walton, E. L., Francastel, C. & Velasco, G. Maintenance of DNA methylation: Dnmt3b joins the dance. Epigenetics 6, 1373–1377 (2011).
pubmed: 22048250
doi: 10.4161/epi.6.11.17978
Hashimshony, T., Zhang, J., Keshet, I., Bustin, M. & Cedar, H. The role of DNA methylation in setting up chromatin structure during development. Nat. Genet. 34, 187–192 (2003).
pubmed: 12740577
doi: 10.1038/ng1158
Charlton, J. et al. TETs compete with DNMT3 activity in pluripotent cells at thousands of methylated somatic enhancers. Nat. Genet. 52, 819–827 (2020).
pubmed: 32514123
pmcid: 7415576
doi: 10.1038/s41588-020-0639-9
Jin, C. et al. TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. Nucleic Acids Res. 42, 6956–6971 (2014).
pubmed: 24875481
pmcid: 4066785
doi: 10.1093/nar/gku372
Eiges, R. et al. Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 1, 568–577 (2007).
pubmed: 18371394
doi: 10.1016/j.stem.2007.09.001
Zhu, C. H. et al. Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging. Cell 6, 515–523 (2007).
pubmed: 17559502
doi: 10.1111/j.1474-9726.2007.00306.x
Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).
pubmed: 24157548
pmcid: 3969860
doi: 10.1038/nprot.2013.143
Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for bisulfite-Seq applications. Bioinformatics 27, 1571–1572 (2011).
pubmed: 21493656
pmcid: 3102221
doi: 10.1093/bioinformatics/btr167
Cohen-Hadad, Y. et al. Marked differences in C9orf72 methylation status and isoform expression between C9/ALS human embryonic and induced pluripotent stem cells. Stem Cell Rep. 7, 927–940 (2016).
doi: 10.1016/j.stemcr.2016.09.011